Categories

  • No categories

Contact us

  • 121 King Street, Melbourne Australia.
  • Email: consalti@example.com
  • Call Us: +36 (0) 1779 228 338
  • +91 9958076020
  • kalranitin2010@gmail.com
Get Request
Transparon Advisory & Consultancy Services
  • Home
  • About Us
    • Our Team
    • Why Transparon
  • Regulatory Services
    • Drug
    • CRO/Global Clinical Trial
    • Biological/Biosimilar
    • Cosmetics
    • Medical Devices
    • Food (FSSAI)
    • In-Vitro
    • Veterinary
  • Contact
Get Request
Transparon Advisory & Consultancy Services
  • Home
  • About Us
    • Our Team
    • Why Transparon
  • Regulatory Services
    • Drug
    • CRO/Global Clinical Trial
    • Biological/Biosimilar
    • Cosmetics
    • Medical Devices
    • Food (FSSAI)
    • In-Vitro
    • Veterinary
  • Contact

Drug Regulatory Services

HomeServicesDrug Regulatory Services
DEFINITIONS OF DRUG

All medicines for internal or external use of human beings or animals and all substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals, including preparations applied on the human body for the purpose of repelling insects like mosquitoes.

“NEW DRUG”

  • drug, including active pharmaceutical ingredient or phytopharmaceutical drug, which has not been used in the country to any significant extent has not been approved as safe and efficacious by Central Licencing Authority (CLAA) i.e. DCG(I) with respect to its claims; or
  • drug approved by the CLAA for certain claims and proposed to be marketed with modified or new claims including indication, route of administration, dosage and dosage form; or
  • a fixed dose combination of two or more drugs, approved by CLAA separately for certain claims and proposed to be combined for the first time in a fixed ratio, or where the ratio of ingredients in an approved combination is proposed to be changed with certain claims including indication, route of administration, dosage and dosage form; or
  • a modified or sustained release form of a drug or novel drug delivery system of any drug approved by the Central Licencing Authority; or
  • a vaccine, r-DNA derived product, living modified organism, monoclonal antibody, stem cell derived product, gene therapeutic product or xenografts, intended to be used as a drug.
  • A new drug which is a modified or sustained release form of a drug or Novel Drug Delivery System (NDDS) of any drug approved by the Central Licencing Authority; or a vaccine, recombinant Deoxyribonucleic Acid (r-DNA) derived product, living modified organism, monoclonal antibody, stem cell derived product, gene therapeutic product or xenografts, intended to be used as drug shall continue to be a new drug forever. However, new drugs covered other than above categories shall be considered as a new drug for a period of 4 years of their approval by the CLA.

    “INVESTIGATIONAL NEW DRUG (IND)” 

    An “investigational new drug (IND)” means a new chemical or biological entity or substance that has not been approved for marketing as a drug in any country.

    “SUBSEQUENT NEW DRUG”

    A subsequent new drug means a drug approved by the Central Licencing Authority for certain claims and proposed to be marketed with modified or new claims including indication, route of administration, dosage and dosage form. A subsequent new drug also includes a new drug already approved in the country

    Regulation of Drugs

    The regulation of Drugs in India, with respect to manufacturing and importing of drugs is primarily governed by the Drugs and Cosmetic Act and Rules , New Drug and Clinical Trials Rules 2019 and various other regulations that are issued by the Government from time to time. These regulations are implemented in India by a 3 tier system, i.e., the Central Drug Standard and Control Organisation(CDSCO), the Zonal offices of CDSCO and the State FDA.

    We, at Transparon, help the manufacturers and importers in navigating these regulations at various levels by formulating watertight strategies and infallible dossiers, so that our clients get their approvals in a time bound manner. At Transparon, we guide our clients throughout the various stages of drug approval, constantly monitoring and advising our clients, on  dossier preparation to clinical trials, SEC meetings to  Medical writing, market research to legal documentation, among other services.

    overview of various

    FORMS & FEES

    A clear regulatory strategy and thorough understanding of the regulatory framework under the Drugs & Cosmetics Act 1940 are crucial for obtaining successful approvals from the Licensing Authority. At Transparon, we work closely with importers and manufacturers to prepare and submit regulatory dossiers. Our team’s expertise has proven to be an invaluable asset to our clients, ensuring a smooth and efficient approval process.

    # Form Applied form Approval Recieved form Fees CDSCO SLA
    1 Form 8
    Application For Licence To Import Drugs (Excluding Those Specified In Schedule X) To The Drugs And Cosmetics Rules, 1945
    Form 10
    Licence To Import Drugs (Excluding Those Specified In Schedule X) To The Drugs And Cosmetic Rules, 1945
    Rs.10000/- For One Product
    Rs.1000/- For Additional Product
    2 Form 8A
    Application For Licence To Import Drugs Specified In Schedule X To The Drugs And Cosmetics Rules, 1945
    Form 10A
    Licence To Import Drugs Specified In Schedule X To The Drugs And Cosmetics Rules, 1945
    Rs.10000/- For One Product
    Rs.1000/- For Additional Product
    3 Form 40
    Application To Import Drugs
    Form 41
    License To Import Drugs
    USD 10000 For Plant
    USD 5000 For Product (Per Product)
    4 Form CT-01
    Application For Registration/Renewal Of Ethics Committee Relating To Clinical Trial Or Bioavailability And Bioequivalence Study Or Biomedical Health Research
    Form CT-03
    Grant Of Registration Of Ethics Committee Relating To Biomedical Health Research
    Form CT-02  Grant Of Registration Of Ethics Committee Relating To Clinical Trial Or Bioavailability And Bioequivalence Study
    5 Form CT-04
    Application For Grant Of Permission To Conduct Clinical Trial Of New Drug Or Investigational New Drug
    Form CT-06
    Permission To Conduct Clinical Trial Of New Drug Or Investigational New Drug
    Phase I-Rs.3,00,000/-
    Phase II,III & IV- Rs. 2,00,000/-
    6 Form CT-05
    Application For Grant Of Permission To Conduct Bioavailability Or Bioequivalence Study
    Form CT-07
    Permission To Conduct Bioavailability Or Bioequivalence Study Of New Drug Or Investigational New Drug
    Rs.2,00,000/-
    7 Form CT-08
    Application For Registration/Renewal Of Bioavailability Or Bioequivalence Study Centre
    Form CT-09
    Grant Of Registration Of Bioavailability Or Bioequivalence Study Centre
    Rs.5,00,000/-
    8 Form CT-10
    Application For Grant Of Permission To Manufacture New Drug Or Investigational New Drug For Clinical Trial Or Bioavailability Or Bioequivalence Study Or For Examination, Test And Analysis
    Form CT-11
    Permission To Manufacture New Drug Or Investigational New Drug For Clinical Trial, Bioavailability Or Bioequivalence Study Or For Examination, Test And Analysis
    Rs.5000/- Per Product
    9 Form CT-12
    Application For Grant Of Permission To Manufacture Formulation Of Unapproved Active Pharmaceutical Ingredient For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Form CT-15
    Permission To Manufacture Unapproved Active Pharmaceutical Ingredient For The Development Of Formulation For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Rs.5000/- Per Product
    10 Form CT-13
    Application For Grant Of Permission To Manufacture Unapproved Active Pharmaceutical Ingredient For Development Of Formulation For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Form CT-15
    Permission To Manufacture Unapproved Active Pharmaceutical Ingredient For The Development Of Formulation For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Rs.5000/- Per Product
    11 Form CT-14
    Permission To Manufacture Formulation Of Unapproved Active Pharmaceutical Ingredient For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Form CT-15
    Permission To Manufacture Unapproved Active Pharmaceutical Ingredient For The Development Of Formulation For Test Or Analysis Or Clinical Trial Or Bioavailability Or Bioequivalence Study
    Rs.5000/- Per Product
    12 Form CT-16
    Application For Grant Of Licence To Import New Drug Or Investigational New Drug For Clinical Trial Or Bioavailability Or Bioequivalence Study Or For Examination, Test And Analysis
    Form CT-17
    Licence To Import New Drug Or Investigational New Drug For The Purpose Of Clinical Trial Or Bioavailability Or Bioequivalence Study Or For Examination, Test And Analysis
    Rs.5000/- Per Product
    13 Form Ct-18
    Application For Grant Of Permission To Import New Drug For Sale Or For Distribution
    Form CT-20
    Permission To Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution
    Form CT-19
    Permission To Import New Active Pharmaceutical Ingredient For Sale Or For Distribution
    Rs.5,00,000/-
    Rs.5,00,000/-
    14 Form CT-21
    Application For Grant Of Permission To Manufacture New Drug Formulation For Sale Or For Distribution
    Form Ct-22
    Permission To Manufacture New Active Pharmaceutical Ingredient For Sale Or For Distribution
    Form Ct-23
    Permission To Manufacture Pharmaceutical Formulation Of New Drug For Sale Or For Distribution
    Rs.5,00,000/-
    Rs.5,00,000/-
    15 Form CT-24
    Application For Licence To Import Of Unapproved New Drug For Treatment Of Patients Of Life Threatening Disease In A Government Hospital Or Government Medical Institution
    Form CT-25
    Licence To Import Unapproved New Drug For Treatment Of Patients Of Life Threatening Disease In A Government Hospital Or Medical Institution
    Rs.10,000/-
    16 Form CT-26
    Application For Grant Of Permission To Manufacture Unapproved New Drug But Under Clinical Trial For Treatment Of Patients Of Life Threatening Disease In A Government Hospital Or Medical Institution
    Form CT-27
    Permission To Manufacture Unapproved New Drug But Under Clinical Trial For Treatment Of Patients Of Life Threatening Disease In A Government Hospital Or Medical Institution
    Rs.5000/-
    17 Renewal or Re-Registration
    Form 40-Application for Import of Drugs
    Form 41
    License To Import Drugs
    USD 10000 For Plant
    USD 5000 For Product (Per Product)
    18 Personal Use
    Form 12A Application for the issue of a permit to import small quantities of drugs for personal use
    Form 12 B
    Permit for the import of small quantities of drugs for personal use
    Zero
    19 CT-28
    Application for import of unapproved new drug for Compassionate use for treatment of patients by hospitals or and medical institution
    CT-29
    Grant of licence for import of new drug for compassionate use
    N.A
    20 CT-30
    Application for the permission to manufacture new drug for Compassionate use
    CT-31
    Grant of the permission to manufacture new drug for Compassionate use
    N.A
    • Drug Regulatory Services
    • CRO Regulatory Services
    • Biological Regulatory Services
    • Cosmetics Regulatory Services
    • Medical Devices Regulatory
    • Food Regulatory Services (FSSAI)
    • In-Vitro Diagnostic Kit
    • Veterinary Regulatory Services

    Got any Questions?
    Call us Today!

    Transparon Advisory & Consultancy Services specializes in providing regulatory solutions across the Drugs, Medical Devices, Biologicals, IVDs, Nutraceuticals, Food, and Cosmetic industries. 

    Linkedin-in

    Services

    • Drug Regulatory Services
    • CRO Regulatory Services
    • Biological Regulatory Services
    • Cosmetics Regulatory Services
    • Medical Device Regulatory Services
    • Food Regulatory Services (FSSAI)
    • In-Vitro Diagnostic Kit
    • Veterinary Regulatory Services

    Contact

    • Transparon  Advisory & Consultancy Services LLP
    • kalranitin2010@gmail.com
    • nitin@transparon.com
    • +91 9958076020

    © Transparon Advisory & Consultancy Services 2025 | All Rights Reserved

    • Home
    • About
    • Faq
    • Contact